Telomir Pharmaceuticals, Inc. SEC filings TELO
Telomir Pharmaceuticals, Inc. has 147 filings in SEC EDGAR's recent list, going back to Apr 3, 2023. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 6, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | Oct 27, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 6, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 17, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 16, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| DEFA14A | Additional proxy material | Aug 19, 2026 | — |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| DEF 14A | Proxy statement | Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 8, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 20, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Apr 30, 2026 | Apr 24, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale
|
Apr 24, 2026 | Apr 22, 2026 |
| 8-K |
Current report
Other events
|
Mar 31, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Other events
|
Mar 31, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Mar 27, 2026 | Mar 23, 2026 |
| 10-K | Annual report | Mar 17, 2026 | Dec 31, 2025 |
| DEFM14A | Filing | Feb 19, 2026 | — |
| DEFA14A | Additional proxy material | Feb 19, 2026 | — |
| 8-K |
Current report
Other events
|
Feb 17, 2026 | Feb 17, 2026 |
| 8-K |
Current report
Other events
|
Feb 5, 2026 | Feb 5, 2026 |
| PRER14A | Filing | Feb 5, 2026 | — |
| PRER14A | Filing | Jan 23, 2026 | — |
| 8-K |
Current report
Listing notice
|
Jan 12, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Other events
|
Jan 5, 2026 | Jan 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Dec 22, 2025 | Dec 17, 2025 |
| 8-K |
Current report
Other events
|
Dec 17, 2025 | Dec 17, 2025 |
| PRER14A | Filing | Nov 28, 2025 | — |
| 8-K |
Current report
Other events
|
Nov 24, 2025 | Nov 24, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 20, 2025 | Nov 14, 2025 |
| PREM14A | Filing | Nov 20, 2025 | Nov 20, 2025 |
| 8-K |
Current report
Other events
|
Nov 20, 2025 | Nov 20, 2025 |
| 8-K |
Current report
Other events
|
Nov 12, 2025 | Nov 12, 2025 |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Other events
|
Oct 22, 2025 | Oct 22, 2025 |
| 8-K |
Current report
Material agreement
|
Oct 20, 2025 | Oct 17, 2025 |
| 8-K |
Current report
Other events
|
Oct 14, 2025 | Oct 14, 2025 |
| 8-K |
Current report
Other events
|
Oct 8, 2025 | Oct 8, 2025 |
| 8-K |
Current report
Other events
|
Oct 6, 2025 | Oct 6, 2025 |
| 8-K |
Current report
Other events
|
Sep 18, 2025 | Sep 18, 2025 |
| 8-K |
Current report
Other events
|
Sep 9, 2025 | Sep 9, 2025 |
| 8-K |
Current report
Other events
|
Sep 4, 2025 | Aug 28, 2025 |
| 8-K |
Current report
Other events
|
Aug 27, 2025 | Aug 27, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Other events
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Other events
|
Jul 23, 2025 | Jul 23, 2025 |
| 8-K |
Current report
Other events
|
Jul 22, 2025 | Jul 18, 2025 |
| 8-K |
Current report
Other events
|
Jul 17, 2025 | Jul 17, 2025 |
| 8-K |
Current report
Other events
|
Jun 18, 2025 | Jun 18, 2025 |
| 8-K |
Current report
Other events
|
Jun 11, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Other events
|
Jun 5, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Other events
|
Jun 2, 2025 | Jun 2, 2025 |
| 8-K |
Current report
Other events
|
May 29, 2025 | May 29, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
May 21, 2025 | May 15, 2025 |
| 8-K |
Current report
Unregistered share sale, Other events
|
May 21, 2025 | May 19, 2025 |
| 8-K |
Current report
Other events
|
May 15, 2025 | May 15, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Other events
|
May 7, 2025 | May 7, 2025 |
| 8-K |
Current report
Other events
|
Mar 19, 2025 | Mar 19, 2025 |
| EFFECT | Filing | Feb 28, 2025 | — |
| CORRESP | Letter to the SEC | Feb 26, 2025 | — |
| 8-K |
Current report
Other events
|
Feb 25, 2025 | Feb 25, 2025 |
| 8-K |
Current report
Other events
|
Feb 20, 2025 | Feb 20, 2025 |
| UPLOAD | Letter from the SEC | Feb 20, 2025 | — |
| 8-K |
Current report
Other events
|
Feb 18, 2025 | Feb 18, 2025 |
| S-3 | Shelf registration | Feb 14, 2025 | — |
| 10-K | Annual report | Feb 4, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Other events
|
Jan 28, 2025 | Jan 28, 2025 |
| 8-K |
Current report
Other events
|
Jan 7, 2025 | Jan 7, 2025 |
| 8-K |
Current report
Other events
|
Dec 23, 2024 | Dec 23, 2024 |
| 8-K |
Current report
Auditor change
|
Dec 20, 2024 | Dec 16, 2024 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Dec 11, 2024 | Dec 9, 2024 |
| 8-K |
Current report
Other events
|
Dec 2, 2024 | Dec 2, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 21, 2024 | Nov 18, 2024 |
| 8-K |
Current report
Other events
|
Nov 20, 2024 | Nov 20, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 27, 2024 | Sep 27, 2024 |
| 8-K |
Current report
Other events
|
Sep 3, 2024 | Sep 3, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 24, 2024 | Jun 18, 2024 |
| 10-Q | Quarterly report | May 13, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 15, 2024 | Apr 15, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 12, 2024 | Apr 12, 2024 |
| 10-K | Annual report | Mar 29, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Feb 13, 2024 | Feb 8, 2024 |
| 424B4 | Prospectus | Feb 12, 2024 | — |
| 424B1 | Filing | Feb 12, 2024 | — |
| EFFECT | Filing | Feb 8, 2024 | — |
| CERT | Filing | Feb 8, 2024 | — |
| 8-A12B | Filing | Feb 6, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| CORRESP | Letter to the SEC | Jan 3, 2024 | — |
| S-1/A | Amended registration statement | Jan 3, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2023 | — |
| S-1/A | Amended registration statement | Dec 19, 2023 | — |
| CORRESP | Letter to the SEC | Dec 14, 2023 | — |
| S-1/A | Amended registration statement | Dec 14, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2023 | — |
| S-1 | Registration statement | Nov 14, 2023 | — |
| CORRESP | Letter to the SEC | Nov 13, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2023 | — |
| DRSLTR | Filing | Oct 16, 2023 | — |
| DRS/A | Filing | Oct 16, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 18, 2023 | — |
| DRS | Filing | Aug 14, 2023 | — |
| D | Filing | Apr 3, 2023 | — |
Showing 109 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TELO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1971532
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.